Drugs for Pancreatic Cancer
Find financial assistance programs available for pancreatic cancer drugs.
Abraxane (paclitaxel protein-bound particles; albumin-bound)
Drug company: Bristol Myers Squibb
Abraxane is a microtubule inhibitor used, in combination with gemcitabine, for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.
Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Abraxane:
BMS Oncology Co-Pay Assistance Program
This program provides financial assistance with out-of-pocket deductible, copay, or co-insurance costs for eligible patients with private insurance who have been prescribed Abraxane. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually.
Bristol Myers Squibb Patient Assistance Foundation
BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Abraxane, may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.
Lynparza (olaparib) Capsules/Tablets
Drug company: AstraZeneca
Lynparza is a PARP inhibitor used for the maintenance treatment
of patients with metastatic pancreatic cancer and deleterious
or suspected deleterious germline BRCA mutation, as detected by an FDA-approved test, in adults whose disease
had not progressed after 16 weeks or more of platinum-based chemotherapy in the first-line setting.
AstraZeneca offers 2 financial assistance programs for
patients who have been prescribed Lynparza:
Lynparza Co-pay Savings Program
The patient’s out-of-pocket costs may vary, but this program
aims for eligible patients to pay $0 per month for Lynparza,
with a maximum out-of-pocket savings of $26,000 annually.
This program has no income requirements, but eligible
patients must have private health insurance that partially
covers the medication costs for Lynparza.
AZ&Me Prescription Savings Program
This prescription savings program offers free, mail-based
medication to qualifying patients who have no insurance,
those who have Medicare Part D coverage, and some
patients with Medicare Part B coverage. General eligibility
requirements include limited household income and/or a
life-changing event in the past year that affected the patient’s
finances. Patients with Medicare Part D coverage must
spend 3% of their total household income on prescription
medicines through a Medicare Part D prescription plan
during the current calendar year and must be unable to enroll
in Medicare limited income subsidy.
Patients with Medicare Part B coverage should call 800-292-
6363 for program requirements. Once accepted into the
program, patients will be enrolled for 1 year (with the option
to re-enroll) and a supply of Lynparza (up to 90 days) will be
sent directly to the patient. Refills need to be requested by the
doctor or the patient.
Onivyde (irinotecan liposome injection)
Drug company: Ipsen
Onivyde is a topoisomerase inhibitor used, in combination
with fluorouracil and leucovorin, for the treatment of patients
with metastatic pancreatic cancer whose disease has progressed
after treatment with Gemzar.
Ipsen Cares offers 2 financial assistance programs for patients
Onivyde Copay Program
Eligible patients with private insurance will pay $0 per order
of Onivyde, with a maximum annual benefit of $20,000.
Ipsen Cares Patient Assistance Program
Uninsured patients who meet the income criteria may be
eligible to receive Onivyde at no cost.
Tarceva (erlotinib) Tablets
Drug company: Genentech
Tarceva is a kinase inhibitor used, in combination with
Gemzar, for the treatment of patients with advanced-stage
pancreatic cancer whose cancer has spread, grown, or cannot
be surgically removed and who have not received previous
Genentech Oncology offers 2 financial assistance program
for patients using Tarceva:
Genentech Oncology Co-pay Assistance Program
Patients with private insurance will pay just a $5 copay per prescription of Tarceva, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.
Genentech Patient Foundation
This foundation provides Tarceva free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.
Table. Drugs Prescribed for Pancreatic Cancer
- Drug name (generic name)
- Drug company
- Patient support services
Drug name (generic name)
- Lynparza (olaparib)
- Maintenance treatment
of patients with metastatic
and deleterious or
germline BRCA mutation,
as detected by an
FDA-approved test, in
adults whose disease
had not progressed
after 16 weeks or more
chemotherapy in the
Patient support services
- Lynparza Co-pay Savings Program
AZ&Me Prescription Savings Program
Last modified: April 1, 2022